Abstract: The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

Abstract: The present disclosure relates to substituted thiophene carboxamides and analogues thereof of formula (I) that may be used for protecting plants from bacterial diseases, in particular from bacterial diseases caused by bacteria belonging to the genus Xanthomonas.

Abstract: The present invention relates to insecticidal formulations for vector and pest control with increased contact efficacy, more particularly to insecticidal active ingredient—matrix particles and insecticidal compositions comprising such insecticidal active ingredient—matrix particles, as well as to methods and uses of such insecticidal formulations.

Abstract: A spray vehicle includes at least one boom, a plurality of spray units, at least one first actuator, at least one second actuator, a plurality of sensors, and a processing unit. The spray units are configured to spray pollen or a liquid chemical. The at least one first actuator is configured to move the at least one boom. The at least one second actuator is configured to control the spray units. At least one sensor is configured to measure a speed of the vehicle relative to the ground. At least one sensor is configured to measure an air movement direction relative to the vehicle. At least one sensor is configured to measure an air movement speed relative to the vehicle. The processing unit is configured to determine an air movement direction relative to the ground and determine an air movement speed relative to the ground.

Abstract: The invention provides for compositions and methods that are useful for repelling birds from crop plants, more particularly repelling birds from feeding on crop plant propagation material, e.g. seeds.

Abstract: The invention relates to a method for transferring a pourable medium (10) from a first vessel (12) into a second vessel (14), by means of a robot arm (16), wherein a movement 118) of the robot arm (16) can be controlled by at least one movement parameter (BP), including, inter alia, the following method steps: d) determining the mass of the medium (10) transferred into the second vessel (14) as an actual filling mass (IFM), and also the variation over time of the actual filling mass (IFM) of the medium (30; as an actual mass flow (IMS), by means of a balance 124), c) calculating a correcting mass flow (StMS) as a correcting variable (26) of a first control circuit (28) while taking into account the actual filling mass (FM) and the intended filling mass (SFM), f) using the correcting variable (26) of die first control circuit (28) as a reference variable (SO) of a second control circuit (32) for the purpose that the calculated correcting mass flow (StMS) is used as the intended mass flow (SMS), g) calculating

Abstract: (alpha-2C) antagonists, in particular substituted piperidinyl-pyrimidinyl-tetra hydrochinolines and piperidinyl-pyridinyl-tetrahydrochinolines of formula (I) for the use in a method for the treatment and/or prophylaxis of sleep-related breathing disorders, preferably obstructive and central sleep apneas and snoring. Formula (I) in which X is a group (A) or (B).

Abstract: The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Abstract: Pharmaceutical Combination for the Treatment of Cancer The present invention relates to combinations of at least two components, component A and component B for use in the treatment of cancer, component A being an anti-CEACAM6 antibody and component B being an anti-PD-1 antibody, preferentially nivolumab, or pembrolizumab, or an anti-PD-L1 antibody, preferentially atezolizumab, avelumab, or durvalumab.

Abstract: The present invention relates to a method of reducing crop damage by treating the seed of the crop with the safener before sowing. This can be done in addition to the use of crop protection combinations/compositions, in particular herbicide/safener combinations and compositions comprising thereof, which are highly suitable to protect crops from herbicide damage in pre- and post-emergence treatments.

Abstract: The present invention relates to a novel process for preparing and isolating 3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide (Isotianil), which can be used as an active compound with microbicidal properties, wherein the amount of waste materials—e.g. solvents and diluents—is significantly reduced and the process meets the requirements of industrial scale production, in particular that it provides the product in high yield, high purity, i.e. minimum amount of by-products and impurities, and can be carried out with tolerable corrosivity in industrial scale metal, in particular stainless steel, vessels or Cr—Ni—Mo alloy pressure filters or centrifuges.

Abstract: The present invention relates to tetrazolylpropyl derivatives of formula (I) wherein one of V1 and V2 represents CR3 and the other one of V1 and V2 represents N, Q represents a 6-membered aromatic cycle as defined in the specification, and R1, R2, R3, R4, and R5 are defined as disclosed in the specification, to compositions comprising such compounds, to the use of said compounds as fungicides, as well as to particular intermediates useful in the synthesis of said tetrazolylpropyl derivatives.

Abstract: The present disclosure relates to an asset tracking apparatus. The asset tracking apparatus includes a plurality of RFID tags and a RFID receiver. The plurality of RFID tags are configured to attach to a plurality of objects. Each object of the plurality of objects can have attached to it a different RFID tag of the plurality of RFID tags. The RFID receiver includes a plurality of RFID antennas. The plurality of RFID antennas are configured to be associated with an object support structure. The object support structure is configured such that one or more objects of the plurality of objects can be placed on the object support structure. The RFID receiver is configured to detect a signal transmitted from an RFID tag attached to an object of the plurality of objects when the object is supported by the object support structure.

Abstract: The present invention covers 2-[(3R)-3-methylmorpholin-4-yl]-4-(1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (in the following called “Compound A”), an inhibitor of ATR kinase, for use in a method of treating a hyper-proliferative disease in a subject.

Abstract: The present invention covers substituted 6-(1H-pyrazol-1-yl)pyrimidin-4-amine compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular and renal diseases, as a sole agent or in combination with other active ingredients.

Abstract: The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle.

Abstract: A spray vehicle includes at least one boom, a plurality of spray units, a plurality of sensors, a processing unit, and an output unit. The plurality of spray units are attached to the at least one boom. The spray units are configured to spray a liquid chemical. At least one sensor is configured to measure a speed of the vehicle relative to the ground. At least one sensor is configured to measure an air movement direction relative to the vehicle. At least one sensor is configured to measure an air movement speed relative to the vehicle. The processing unit is configured to determine an air movement direction relative to the ground and determine an air movement speed relative to the ground. The processing unit is configured to generate a spray record for an environment within which the vehicle is operating. The output unit is configured to output the spray record.

Abstract: The invention relates to a process for producing pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and to the use of the dosage forms obtained by the said production process to treat and/or prevent breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.

Abstract: The present invention relates to reversal agents, which specifically bind to the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D as described in WO2013/167669, and neutralize the therapeutic activity of this anti-FXIa antibody, as well as to compositions comprising these reversal agents. Methods of obtaining the antibodies or antigen-binding fragments thereof (such as Fab fragments) and nucleic acids encoding the same, are also provided. Furthermore, the invention relates to methods of use of these reversal agents, such as methods for neutralizing the therapeutic activity of the anti-FXIa antibody 076D-M007-H04-CDRL3-N110D, and to related methods as essential part of a general bleeding management.

Abstract: The present disclosure relates to the technical field of magnetic resonance tomography. The present disclosure relates to a method, a system and a computer program product for determining different states of a contrast agent in different types of tissue in a magnetic resonance fingerprinting method.